A recent study found that cytomegalovirus (CMV) reactivation is a significant complication among CMV-seropositive patients who undergo chimeric antigen receptor (CAR) T-cell therapy.
Study Highlights High Risk of Cytomegalovirus Reactivation in Patients Treated With CAR T-Cell Therapy
Tori Gustafson2024-08-26T17:28:26+00:00August 26th, 2024|multiple myeloma|Comments Off on Study Highlights High Risk of Cytomegalovirus Reactivation in Patients Treated With CAR T-Cell Therapy